Englander Institute for Precision Medicine

A person’s “bioenergetic age” — or how youthfully their cells generate energy — might be a key indicator of whether they’re at risk of developing Alzheimer’s disease, new research from Weill Cornell Medicine shows.

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell Medicine investigators.

Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell Medicine investigators. 

Two Weill Cornell Medicine physician-scientists, Dr. Niroshana Anandasabapathy and Dr. Rohit Chandwani, have been elected members of the American Society for Clinical Investigation (ASCI) for 2025.

The distinct population of endothelial cells that line blood vessels in the insulin-producing “islets” of the human pancreas have been notoriously difficult to study, but Weill Cornell Medicine investigators have now succeeded in comprehensively detailing the unique characteristics of these cells. 

Drs. Steven Josefowicz, Ekta Khurana and Kristen Pleil were among 400 early-career scientists and engineers to receive the Presidential Early Career Award for Scientists and Engineers.

Prostate cancer hijacks the normal prostate’s growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers.

Three teams led by Weill Cornell Medicine scientists have received awards from the Starr Cancer Consortium in its 17th and final annual grant competition

A new artificial intelligence-based system can accurately assess the chromosomal status of in vitro-fertilized (IVF) embryos using only time-lapse video images of the embryos and maternal age, according to a study from investigators at Weill Cornell Medicine.

How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center. 

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a multicenter study conducted at Weill Cornell Medicine, Memorial Sloan Kettering, and other institutions.

Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor therapy, according to a preclinical study led by researchers at Weill Cornell Medicine.

A powerful new analytical tool offers a closer look at how tumor cells “shape-shift” to become more aggressive and untreatable, as shown in a study from researchers at Weill Cornell Medicine and the New York Genome Center.

Scientists at Weill Cornell Medicine in Qatar (WCM-Q) have created an intricate molecular map of the human body and its complex physiological processes based on the analysis of thousands of molecules measured in blood, urine and saliva samples from 391 volunteers.

Researchers at Weill Cornell Medicine have used artificial intelligence to identify drug targets based on mapping regulatory networks in patient tumors.

A team co-led by researchers at Weill Cornell Medicine and the New York Genome Center has developed an advanced method for revealing how gene mutations disrupt the normal packaging of DNA. 

Weill Cornell Medicine is part of an international team that has been awarded funding of up to $25 million over five years by Cancer Grand Challenges to study the causes of cancer inequities.

Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators.

Weill Cornell Medicine researchers received a $2.4 million grant from the U.S. Department of Defense Breast Cancer Research Program to validate a new blood test for the early detection of breast cancer.

A historic investment from Board of Fellows member Israel Englander will advance Weill Cornell Medicine’s growing research enterprise and support critical initiatives throughout the institution.